WorksAgricultural and Biological Sciences
From antidepressants to psychedelics: revisiting the pharmacology of so-called serotoninergic treatments
Abstract
Recent years have seen a resurgence of interest in serotoninergic psychedelics as potential treatment for diverse psychiatric disorders. Here, we will delve into the molecular mechanisms of drugs used to treat depression and obsessive-compulsive disorder (OCD), with implications on the mechanism of action of so-called ''serotoninergic'' psychedelics as well as selective serotonin reuptake inhibitors (SSRIs). In particular, we argue that the pharmacokinetic and pharmacodynamic properties of SSRIs suggest that the inhibition of the serotonin transporter (SERT) alone does not provide a comprehensive account of their clinical effects. On the contrary, the SSRI posology required to treat depression and OCD is consistent with their major molecular target(s) displaying an SSRI affinity much lower than SERT. Such is the case for the tyrosine receptor kinase B (TrkB), recently described as a putative target for drugs with antidepressant effects. TrkB might thus provide a unifying framework for understanding the therapeutic effects of antidepressant drugs. We finally discuss the pharmacological implications of this hypothesis on the therapeutical potential of psychedelics.